Markus Bangerter
-
- Lymphoma Diagnosis and Treatment 17
- Genetics top 2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 11
- Chronic Lymphocytic Leukemia Research 5
-
- Medical Imaging Techniques and Applications 9
- Hematology top 5%
- Chronic Myeloid Leukemia Treatments 11
- Platelet Disorders and Treatments 6
- Acute Myeloid Leukemia Research 4
- Multiple Myeloma Research and Treatments 4
- Neurology top 5%
- Co-authors
- Martin GrießhammerFlorian MoogNorbert FrickhofenS N ReskeAlbrecht GuhlmannJ. KotzerkeElmar M. MerkleC. G. Diederichs
- Partner nations
- GermanyUnited StatesEstonia
In The Last Decade
Markus Bangerter
37 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 75
- Pathology and Forensic Medicine 914
- Genetics 521
- Radiology, Nuclear Medicine and Imaging 750
- Hematology 337
- Neurology 243
Countries citing papers authored by Markus Bangerter
This map shows the geographic impact of Markus Bangerter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Bangerter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Bangerter more than expected).
Fields of papers citing papers by Markus Bangerter
This network shows the impact of papers produced by Markus Bangerter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Bangerter. The network helps show where Markus Bangerter may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Markus Bangerter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110) | 2017 | 2 |
| 2 | 2015 | 0 | |
| 3 | 2011 | 7 | |
| 4 | 2007 | 38 | |
| 5 | 2001 | 15 | |
| 6 | 2000 | 11 | |
| 7 | 2000 | 25 | |
| 8 | 1999 | 12 | |
| 9 | 1999 | 25 | |
| 10 | 1998 | 227 | |
| 11 | 1998 | 6 | |
| 12 | 1998 | 185 | |
| 13 | 1997 | 229 | |
| 14 | 1997 | 13 | |
| 15 | 1997 | 23 | |
| 16 | 1997 | 9 | |
| 17 | 1997 | 45 | |
| 18 | 1997 | 13 | |
| 19 | 1996 | 29 | |
| 20 | 1996 | 14 |
About Markus Bangerter
Markus Bangerter is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 39 papers that have together received 1.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (17 papers), Chronic Myeloid Leukemia Treatments (11 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), Medical Imaging Techniques and Applications (9 papers), Platelet Disorders and Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Acute Myeloid Leukemia Research (4 papers) and Multiple Myeloma Research and Treatments (4 papers). The work is most often cited by research in Pathology and Forensic Medicine (914 citations), Genetics (521 citations) and Radiology, Nuclear Medicine and Imaging (750 citations). Markus Bangerter has collaborated with scholars based in Germany, United States and Estonia. Frequent co-authors include Martin Grießhammer, Florian Moog, Norbert Frickhofen, S N Reske, Albrecht Guhlmann, J. Kotzerke, Elmar M. Merkle, C. G. Diederichs, H. Heimpel and Theodor C. Sauer. Their work appears in journals such as Blood, Acta Cytologica, Annals of Oncology, Annals of Hematology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.